IP Library Granted Patent US 7,977,472
Granted Patent B2
US 7,977,472 · App. 12/765,450 · Granted Jul 12, 2011

RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,977,472
App. No.
12/765,450
Granted
Jul 12, 2011
Kind
B2
Abstract

This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of myostatin genes.

Claims (10)

1. A chemically modified short interfering nucleic acid (siNA) molecule, wherein:

(a) the siNA molecule comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;

(b) each strand is independently 18 to 27 nucleotides in length, and together comprise a duplex having between 17 and 23 base pairs;

(c) the antisense strand is complementary to a human myostatin RNA sequence comprising SEQ ID NO:441;

(d) a plurality of the pyrimidine nucleotides present in the sense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of the purine nucleotides present in the sense strand are 2′-deoxy purine nucleotides; and

(e) a plurality of the pyrimidine nucleotides in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of the purine nucleotides present in the antisense strand are 2′-O-methyl purine nucleotides.

2. The siNA molecule of claim 1 , wherein the sense strand has a cap at both 5′- and 3′-ends of the sense strand.

3. The siNA molecule of claim 1 comprising a 3′-overhang on one or both strands.

4. The siNA molecule of claim 1 , wherein the antisense strand has a phosphorothioate internucleotide linkage at the 3′-end.

5. A composition comprising the siNA molecule of claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
Continuity (18)
Continuation 12185678 · Aug 4, 2008
Continuation 10879867 · Jun 28, 2004
Continuation In Part PCTUS2004016390 · May 24, 2004
Continuation In Part 10826966 · Apr 16, 2004
Continuation In Part 10757803 · Jan 14, 2004
Continuation In Part 10720448 · Nov 24, 2003
Continuation In Part 10693059 · Oct 23, 2003
Continuation In Part 10444853 · May 23, 2003
Continuation In Part PCTUS0305346 · Feb 20, 2003
Continuation In Part PCTUS0305028 · Feb 20, 2003
Provisional Application 60358580 · Feb 20, 2002
Provisional Application 60363124 · Mar 11, 2002
Provisional Application 60386782 · Jun 6, 2002
Provisional Application 60406784 · Aug 29, 2002
Provisional Application 60408378 · Sep 5, 2002
Provisional Application 60409293 · Sep 9, 2002
Provisional Application 60440129 · Jan 15, 2003
Related Publication 20100227912A1 · Sep 9, 2010